ライフサイエンスコーパス: mitral regurgitation

1 tion at 1 year (6.0% of patients with severe mitral regurgitation).

2 l spectrum is associated with higher risk of mitral regurgitation.

3 rategy to improve the lives of patients with mitral regurgitation.

4 pair and replacement in patients with native mitral regurgitation.

5 able to less severe and subclinical cases of mitral regurgitation.

6 ol may be of importance in the prevention of mitral regurgitation.

7 h an increased risk of primary and secondary mitral regurgitation.

8 ter mitral valve repair for the treatment of mitral regurgitation.

9 f the indication for surgery in degenerative mitral regurgitation.

10 antly more recurrences of moderate or severe mitral regurgitation.

11 ef in such patients via reduction of SAM and mitral regurgitation.

12 ts with moderate-to-severe or severe organic mitral regurgitation.

13 of percutaneous interventions for functional mitral regurgitation.

14 ely used in high surgical risk patients with mitral regurgitation.

15 mitral valve repair in patients with primary mitral regurgitation.

16 TR only occurred in those with no/trace/mild mitral regurgitation.

17 us in future repair algorithms for secondary mitral regurgitation.

18 opment of new repair techniques for ischemic mitral regurgitation.

19 , which was similar for FMR and degenerative mitral regurgitation.

20 ntricular size, that governs the severity of mitral regurgitation.

21 ce and severity of LV dysfunction in organic mitral regurgitation.

22 alve disease, particularly in the setting of mitral regurgitation.

23 exhibiting grade III/IV restrictive DD with mitral regurgitation.

24 s novel valve system in patients with severe mitral regurgitation.

25 whether FQs increase the risk of aortic and mitral regurgitation.

26 pproach aiming to treat patients with severe mitral regurgitation.

27 nts with heart failure and 3 to 4+ secondary mitral regurgitation.

28 , and ongoing clinical trials for functional mitral regurgitation.

29 with heart failure and symptomatic secondary mitral regurgitation.

30 reated in Yorkshire swine by inducing severe mitral regurgitation.

31 strain intensity was higher in patients with mitral regurgitation (0.15+/-0.03) than in normals (0.11

32 re were 3950 patients with any VHD: 3101 had mitral regurgitation, 1179 with tricuspid regurgitation,

33 IPMD, mitral valve geometry, and severity of mitral regurgitation, 67 patients with ischemic heart di

34 ed in patients with moderate/severe ischemic mitral regurgitation (9.6 +/- 2.8 mm), but preserved in

35 In patients with HF and severe secondary mitral regurgitation, a short-term change in disease-spe

36 Acute improvement in mitral regurgitation after TAVR is predominantly related

37 absence of SAM and significant reduction in mitral regurgitation, although high systolic LVOT veloci

38 p period, 28,655 (0.52%) were diagnosed with mitral regurgitation and a further 1,262 (0.02%) were di

39 in significantly reduced rates of recurrent mitral regurgitation and adverse cardiac events over tim

40 superior repair with decreased recurrence of mitral regurgitation and enhanced reversal of left ventr

41 ustained 1-year reduction of the severity of mitral regurgitation and improvement of clinical symptom

42 It can manifest as mitral regurgitation and is the leading indication for m

43 p < 0.0001) and after further adjustment for mitral regurgitation and pacemaker/defibrillator (HR: 0.

44 In asymptomatic patients with >/=3+ mitral regurgitation and preserved left ventricular (LV)

45 1+/-12 years and 69% men) with >/=3+ primary mitral regurgitation and preserved left ventricular ejec

46 ymptomatic patients with significant primary mitral regurgitation and preserved left ventricular ejec

47 cardiac magnetic resonance and no or trivial mitral regurgitation, and 16 (6 female patients; median

48 er age, female sex, lower ejection fraction, mitral regurgitation, and atrial fibrillation (all P<0.0

49 lve repair in patients with severe secondary mitral regurgitation, and implantable cardiac defibrilla

50 et mobility, decreased severity of recurrent mitral regurgitation, and improved reverse remodeling wi

51 lmonale, left ventricular ejection fraction, mitral regurgitation, and inferior vena cava variability

52 ctly during ventricular systole resulting in mitral regurgitation, and it is associated with sudden c

53 controls and patients with aortic stenosis, mitral regurgitation, and left ventricular assist device

54 ree survival was predicted by age, degree of mitral regurgitation, and postprocedural hemodynamic dat

55 etic resonance (CMR) can accurately quantify mitral regurgitation, and we examined whether this was a

56 ography evidence of at least moderate aortic/mitral regurgitation, aortic stenosis, or prior valve su

57 ng severe or mild/moderate LV dysfunction in mitral regurgitation are doubted and poorly followed in

58 linical outcomes after surgical treatment of mitral regurgitation are worse if intervention occurs af

59 e also treated with the MitraClip system for mitral regurgitation as a combined procedure.

60 recommended in patients with severe primary mitral regurgitation as soon as ejection fraction (EF) <

61 ncreased left atrial pressure and stiffness, mitral regurgitation, as well as features of metabolic s

62 owed a persistent reduction in the degree of mitral regurgitation at 1 year (6.0% of patients with se

63 The rate of moderate or severe recurrence of mitral regurgitation at 12 months was higher in the repa

64 f death was only found in those with minimal mitral regurgitation at baseline.

65 06; P = .02), presence of moderate or severe mitral regurgitation at discharge (1.65; 95% CI, 1.21-2.

66 ery disease, heart failure, aortic stenosis, mitral regurgitation, atrial fibrillation, ischemic stro

67 Forty-one patients with severe mitral regurgitation being considered for transcatheter

68 s) undergoing primary repair of degenerative mitral regurgitation between 2003 and 2011, 419 (65%) un

69 h a reduced prevalence of moderate or severe mitral regurgitation but an increased number of untoward

70 repair provided a more durable correction of mitral regurgitation but did not significantly improve s

71 is preferable over replacement for rheumatic mitral regurgitation but is not available to the vast ma

72 h a reduced prevalence of moderate or severe mitral regurgitation, but patients had more adverse even

73 cement provided a more durable correction of mitral regurgitation, but there was no significant betwe

74 ) is a recent percutaneous approach to treat mitral regurgitation by placement of MC in the center of

75 ventricular size, shape, and mass and reduce mitral regurgitation by reverse remodeling of the failin

76 tion and preservation for surgical repair of mitral regurgitation caused by prolapse.

77 ty of tricuspid regurgitation, or individual mitral regurgitation characteristics.

78 y for Heart Failure Patients With Functional Mitral Regurgitation [COAPT]; NCT01626079).

79 remodeling in patients with chronic primary mitral regurgitation (CPMR).

80 c, severe functional, degenerative, or mixed mitral regurgitation deemed at high risk or inoperable.

81 y for Heart Failure Patients With Functional Mitral Regurgitation) demonstrated that edge-to-edge tra

82 DMD does not incur more severe mitral regurgitation, despite larger prolapse and valve

83 in follow-up intervals for TTE assessment of mitral regurgitation, despite risk-adjustment for patien

84 ndependent of age, end-systolic volume, sex, mitral regurgitation, diabetes mellitus, dyslipidemia, c

85 fibrillation (AF) complicating degenerative mitral regurgitation (DMR) a debated indication for surg

86 with symptomatic functional or degenerative mitral regurgitation (DMR) at high surgical risk.

87 rial enlargement is frequent in degenerative mitral regurgitation (DMR), but its link to outcomes rem

88 ns the gold standard for severe degenerative mitral regurgitation (DMR).

89 tween EF and mortality in 1875 patients with mitral regurgitation due to flail leaflets in sinus rhyt

90 Proper identification of these severe mitral regurgitation due to these disease valves will he

91 ecific subgroups of patients with functional mitral regurgitation (eg, disproportionate versus propor

92 time, ejection time, total isovolumic time, mitral regurgitation, ejection fraction, and blood press

93 impairs their systolic closure, resulting in mitral regurgitation, even in small ventricles.

94 Only patients with functional mitral regurgitation experienced significant reduction o

95 The prevalent pathogenesis was functional mitral regurgitation (FMR) (n = 452 [72.0%]).

96 and medical treatment options for functional mitral regurgitation (FMR) are limited and additional in

97 c left ventricular (LV) function, functional mitral regurgitation (FMR), and pulmonary hypertension (

98 AR, and 167 (14%) had AR + MR (9% functional mitral regurgitation [FMR] [84% nonischemic] and 5% orga

99 quantified as risk factors for recurrence of mitral regurgitation following reduction annuloplasty.

100 py has emerged as an option for treatment of mitral regurgitation for selected, predominantly high-ri

101 tery disease and moderate or severe ischemic mitral regurgitation from 1990 to 2009, categorized by m

102 r mitral valve repair (MitraClip) for severe mitral regurgitation from 2007 to 2013 as part of the EV

103 nts with heart failure and 3 to 4+ secondary mitral regurgitation from the perspective of the US heal

104 dient was 7 mm Hg, most patients (96.7%) had mitral regurgitation grade <=1 (+) and were in New York

105 - 11 mm Hg to 20 +/- 8 mm Hg; p = 0.06), and mitral regurgitation grade (3.0 +/- 0 vs. 0.8 +/- 0.4; p

106 ts with echocardiographic moderate or severe mitral regurgitation had baseline CMR scans and were fol

107 ether FQs can increase the risk of aortic or mitral regurgitation has not been studied.

108 Patients with organic mitral regurgitation have higher strain than normals.

109 SBP was associated with a 26% higher risk of mitral regurgitation (hazard ratio [HR] 1.26; CI 1.23, 1

110 athy of unknown etiology that predisposes to mitral regurgitation, heart failure and sudden death.

111 maller LA volumes, better function, and less mitral regurgitation, HFpEF patients had more atrial fib

112 dence interval [CI] 2.77-11.33), presence of mitral regurgitation (HR 8.13, 95% CI 4.09-12.16), lower

113 HR: 2.9; 95% CI: 1.5 to 5.4; p < 0.001), and mitral regurgitation (HR: 5.0; 95% CI: 1.5 to 17.1; p =

114 Of all patients, mitral regurgitation improved in 54%, remained the same

115 In ischemic mitral regurgitation (IMR), ring annuloplasty is associa

116 Mitral regurgitation in people without prior cardiac dis

117 (mean age, 61 years +/- 19; nine male) with mitral regurgitation in the 24 hours before mitral valve

118 Despite the prevalence of mitral regurgitation in the elderly population, however,

119 Despite the anatomical complexity of mitral regurgitation in the patients in this compassiona

120 eatment of asymptomatic patients with severe mitral regurgitation in valve reference centres, in whic

121 clinical risk factors, severity of ischemic mitral regurgitation, incomplete revascularization, and

122 cal risk factors, end-systolic volume index, mitral regurgitation, incomplete revascularization, and

123 At 1 month after mitral regurgitation induction, pigs developed HF as evi

124 One month after mitral regurgitation induction, pigs were randomized to

125 s; median EF, 66% [60%-71%]) enrolled in the Mitral Regurgitation International Database (MIDA) regis

126 MIDA (Mitral Regurgitation International Database) is a multic

127 Patients were enrolled in the MIDA (Mitral Regurgitation International Database) registry, w

128 Severe mitral regurgitation is a common and complex disease tha

129 Ischemic mitral regurgitation is associated with a substantial ri

130 Severe mitral regurgitation is associated with impaired prognos

131 Ischemic mitral regurgitation is associated with increased mortal

132 Mitral regurgitation is frequently associated with ventr

133 ese results show that the risk of aortic and mitral regurgitation is highest with current use followe

134 Surgery for severe mitral regurgitation is indicated if symptoms or left ve

135 ographic (TTE) surveillance of patients with mitral regurgitation is indicated to avoid adverse ventr

136 n (eg, disproportionate versus proportionate mitral regurgitation) is key to the success of new devic

137 placement, thickness, coaptation height, and mitral regurgitation jet height (all P<0.05).

138 ons onto the annulus, coaptation height, and mitral regurgitation jet height in 261 Framingham Offspr

139 iteria, first tested in a preliminary phase, mitral regurgitation jet length>/=2 cm or any aortic reg

140 s with MVP (17%) had moderate or more severe mitral regurgitation (jet height >/=5 mm) and 5 others (

141 Significant myxomatous mitral regurgitation leads to progressive left ventricul

142 Clinical and echocardiographic data (mitral regurgitation, LV ejection fraction, LV dimension

143 In patients with secondary mitral regurgitation, mainly a disease of the left ventr

144 age and postprocedural variables, including mitral regurgitation, mean gradient, and pulmonary press

145 on the long-term association between SBP and mitral regurgitation (mediator-adjusted HR 1.22; CI 1.20

146 itral valve annuloplasty (RMA) for secondary mitral regurgitation might cause functional mitral steno

147 ViR group had more frequent post-procedural mitral regurgitation moderate or higher (19.4% vs. 6.8%;

148 lar ejection fraction, worse post-procedural mitral regurgitation, moderate or severe lung disease, d

149 lve (MV) disease is a common cause of severe mitral regurgitation (MR) and accounts for the majority

150 in some but not all patients with secondary mitral regurgitation (MR) and heart failure (HF).

151 The relationship between treatment of mitral regurgitation (MR) and renal function is not well

152 uretic peptide (BNP) may predict outcomes of mitral regurgitation (MR) are plagued by small size, inc

153 gradient >=10 mm Hg and significant residual mitral regurgitation (MR) as >= moderate.

154 l aggregation has been described for primary mitral regurgitation (MR) caused by mitral valve prolaps

155 alternative for patients with severe primary mitral regurgitation (MR) considered at high or prohibit

156 Severe mitral regurgitation (MR) conveys significant morbidity

157 g its determinants or its effect on ischemic mitral regurgitation (MR) development.

158 ) repair has become the standard therapy for mitral regurgitation (MR) due to degenerative diseases,

159 Patients with severe mitral regurgitation (MR) due to isolated posterior prol

160 The development of secondary mitral regurgitation (MR) due to left ventricular dysfun

161 The risk for and consequences of recurrent mitral regurgitation (MR) following degenerative mitral

162 stratification of patients with significant mitral regurgitation (MR) has not been studied.

163 (5.3%), mitral stenosis (MS) in 234 (4.5%), mitral regurgitation (MR) in 1114 (21.3%, primary in 746

164 Two distinct pathways can lead to functional mitral regurgitation (MR) in patients with chronic heart

165 ications and suitable operative strategy for mitral regurgitation (MR) in patients with HOCM.

166 This study aimed to evaluate treatment of mitral regurgitation (MR) in patients with severe DMR at

167 Unlike secondary mitral regurgitation (MR) in the setting of left ventric

168 Treatment of mitral regurgitation (MR) in the setting of severe mitra

169 bbott Vascular, Santa Clara, California) for mitral regurgitation (MR) in the United States.

170 t subclavian artery, misdiagnosed as primary mitral regurgitation (MR) in transthoracic echocardiogra

171 Mitral regurgitation (MR) is a common valvular heart dis

172 ral valve repair (TMVr) for the treatment of mitral regurgitation (MR) is a complex procedure that re

173 Mitral regurgitation (MR) is a complex valve lesion that

174 Mitral regurgitation (MR) is a complex valve lesion that

175 Primary mitral regurgitation (MR) is a growing health problem du

176 Symptomatic mitral regurgitation (MR) is associated with high morbid

177 Secondary mitral regurgitation (MR) is associated with poor outcom

178 Mitral regurgitation (MR) is associated with worse survi

179 Significant mitral regurgitation (MR) is frequent in patients with s

180 Mitral regurgitation (MR) is one of the most prevalent v

181 ere aortic stenosis and concomitant relevant mitral regurgitation (MR) is present in 30% to 55% of th

182 Severe primary (degenerative) mitral regurgitation (MR) is repaired with durable resul

183 Mitral regurgitation (MR) is the most common type of val

184 Mitral regurgitation (MR) is the most common valve disea

185 Mitral regurgitation (MR) is the most common valvular he

186 s with symptomatic HF and 3+ to 4+ secondary mitral regurgitation (MR) on maximally-tolerated medical

187 Etiology, mechanisms, and survival of mitral regurgitation (MR) plus hemodynamically-significa

188 nts with chronic severe primary degenerative mitral regurgitation (MR) remains controversial, and fur

189 All patients treated had functional mitral regurgitation (MR) secondary to ischemic cardiomy

190 tic patients make the accurate assessment of mitral regurgitation (MR) severity even more important.

191 echocardiographic parameters when evaluating mitral regurgitation (MR) severity.

192 outcomes of AKI in patients with significant mitral regurgitation (MR) undergoing transcatheter valve

193 onsecutive patients with severe degenerative mitral regurgitation (MR) were treated with a mitral val

194 be overestimated in patients with secondary mitral regurgitation (MR) when using LV ejection fractio

195 ic patients with either primary or secondary mitral regurgitation (MR) who were at high or prohibitiv

196 lve Edge-to-Edge Repair Study), treatment of mitral regurgitation (MR) with a novel percutaneous devi

197 ering by displaced papillary muscles induces mitral regurgitation (MR), which doubles mortality.

198 herapy for patients with symptomatic, severe mitral regurgitation (MR).

199 nd surgery for patients with severe ischemic mitral regurgitation (MR).

200 nt of prohibitive-risk patients with primary mitral regurgitation (MR).

201 ction in volume overload induced by isolated mitral regurgitation (MR).

202 rformed without annuloplasty in degenerative mitral regurgitation (MR).

203 n (TR) may affect prognosis in patients with mitral regurgitation (MR).

204 Only patients with functional mitral regurgitation (n = 71) experienced an acute reduc

205 on fraction, 60% [45%-67%]; all </= moderate mitral regurgitation; n=6 with previous cardiac arrest a

206 Mitral regurgitation occurs from leaflet coaptation fail

207 l patients, resulting in procedural residual mitral regurgitation of grade 2+ or less in 22 (96%) pat

208 d for the quantitative assessment of organic mitral regurgitation (OMR).

209 ation [FMR] [84% nonischemic] and 5% organic mitral regurgitation [OMR] [62% degenerative]).

210 The rate of recurrence of moderate or severe mitral regurgitation over 2 years was higher in the repa

211 MVP progresses to significant mitral regurgitation over a period of 3 to 16 years in o

212 (95.4%) and similar in FMR and degenerative mitral regurgitation (p = 0.662).

213 Mean age was 77+/-14 years; 71% male (n=29); mitral regurgitation pathogenesis was functional in 54%

214 rate-to-severe (3+) or severe (4+) secondary mitral regurgitation, patients treated with transcathete

215 2000 and December 2011 (excluding functional mitral regurgitation, prior valvular surgery, hypertroph

216 nce and severity of coronary artery disease, mitral regurgitation, pulmonary hypertension, right vent

217 Mitral regurgitation recurred more frequently in the rep

218 2014, with hospital mortality of 2% and with mitral regurgitation reduced to grade </=2 in 87% of pat

219 greater tubular ascending aorta, presence of mitral regurgitation, reduced left ventricular ejection

220 ographic core analysis after 6 months showed mitral regurgitation reduction in 50% of treated patient

221 ular and atrial dimensions (all P>0.55), and mitral regurgitation regurgitant orifice (P=0.62).

222 The optimal treatment for ischemic mitral regurgitation remains actively debated.

223 % versus 69%; P=0.003), and in patients with mitral regurgitation, reproducibility was improved with

224 months for severe, moderate, mild, and trace mitral regurgitation, respectively, with 20% of provider

225 alysis, exercise ejection fraction, exercise mitral regurgitation, rest and exercise tricuspid annula

226 s in the COAPT trial with 3+ or 4+ secondary mitral regurgitation, selected using strict echocardiogr

227 spid valve, moderate aortic stenosis, severe mitral regurgitation, severe aortic regurgitation, or su

228 There was an interaction between TR and mitral regurgitation severity (P=0.04); the increased ha

229 le quantitation of cardiac remodeling and of mitral regurgitation severity and of annular and valvula

230 raphic algorithm was implemented for grading mitral regurgitation severity during the screening proce

231 ent depression (all p < 0.0001) but not with mitral regurgitation severity or ejection fraction.

232 h rate of technical success and reduction of mitral regurgitation severity.

233 ggravating role of tissue paucity of FED) on mitral regurgitation severity.

234 ificant difference in these results based on mitral regurgitation severity.

235 t ventricular (LV) dysfunction and secondary mitral regurgitation (SMR) are still controversial.

236 Secondary mitral regurgitation (SMR) occurs in the absence of orga

237 quantitative assessment of severe secondary mitral regurgitation (sMR) reflect the lacking link of t

238 tients with heart failure (HF) and secondary mitral regurgitation (SMR).

239 nd then according to atrial fibrillation and mitral regurgitation status.

240 with outcomes, mixed data on SMR and primary mitral regurgitation, studies not clearly reporting the

241 In primary mitral regurgitation, surgical repair is the standard of

242 One hundred four patients with degenerative mitral regurgitation surgically amenable to either leafl

243 AS) was significantly lower in patients with mitral regurgitation than in healthy control subjects (P

244 High Risk Patients with Severe, Symptomatic Mitral Regurgitation - The Twelve Intrepid TMVR Pilot St

245 y for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626

246 y for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial]; NCT01626079).

247 In patients with moderate ischemic mitral regurgitation, the addition of mitral-valve repai

248 After mitral valve repair for primary mitral regurgitation, the preoperative LVEI is a new and

249 flow tract (LVOT) obstruction and associated mitral regurgitation, thereby leading to amelioration of

250 nts with heart failure and 3 to 4+ secondary mitral regurgitation, TMVr increases life expectancy and

251 assigned 301 patients with moderate ischemic mitral regurgitation to CABG alone or CABG plus mitral-v

252 he role of EF in a large registry of organic mitral regurgitation to objectively establish thresholds

253 y assigned 251 patients with severe ischemic mitral regurgitation to undergo either mitral-valve repa

254 ay determine whether the lower prevalence of mitral regurgitation translates into a net clinical bene

255 o evaluate the relationship between ischemic mitral regurgitation treatment strategy and survival.

256 y for Heart Failure Patients With Functional Mitral Regurgitation), treatment of heart failure (HF) p

257 y for Heart Failure Patients with Functional Mitral Regurgitation) trial among patients with heart fa

258 y for Heart Failure Patients with Functional Mitral Regurgitation) trial, 614 patients with HF with m

259 y for Heart Failure Patients With Functional Mitral Regurgitation) trial, transcatheter mitral valve

260 y for Heart Failure Patients with Functional Mitral Regurgitation) trial, transcatheter mitral valve

261 y for Heart Failure Patients With Functional Mitral Regurgitation) trial.

262 tery disease and moderate or severe ischemic mitral regurgitation undergoing CABG alone demonstrated

263 In patients with moderate ischemic mitral regurgitation undergoing CABG, the addition of mi

264 tients with grade III+ or greater myxomatous mitral regurgitation undergoing exercise echocardiograph

265 ship between blood pressure (BP) and risk of mitral regurgitation using Cox regression models.

266 te-to-severe (grade 3+) or severe (grade 4+) mitral regurgitation using the Edwards PASCAL TMVr syste

267 to reduce systolic anterior motion (SAM) and mitral regurgitation using the transcatheter mitral clip

268 odynamic disorders can result from eccentric mitral regurgitation usually caused by chordae tendinae

269 Mitral regurgitation was <=2+ in all the cases and mean

270 ion II score and presence of sepsis, whereas mitral regurgitation was associated with longer hospital

271 CMR quantification of mitral regurgitation was associated with the development

272 h subpapillary infarction and impaired IPMD, mitral regurgitation was evident within 1 week, compared

273 e 2-year rate of moderate or severe residual mitral regurgitation was higher in the CABG-alone group

274 Moderate or severe mitral regurgitation was less common in the combined-pro

275 At 12 months, moderate mitral regurgitation was observed in 3 subjects in the l

276 PERM) by these proximate causes of secondary mitral regurgitation was only 13% (CI 6.1%, 20%), and ac

277 ve repair in patients with moderate ischemic mitral regurgitation, we found no significant difference

278 replacement in patients with severe ischemic mitral regurgitation, we found no significant difference

279 ve repair or replacement for severe ischemic mitral regurgitation, we observed no significant between

280 d that patients with </= mild postprocedural mitral regurgitation were 4-fold more likely to experien

281 ho underwent mitral valve repair for primary mitral regurgitation were studied.

282 ariable analysis, the predictors of improved mitral regurgitation were the decrease of tenting area (

283 stolic volume was increased in patients with mitral regurgitation when compared with that in healthy

284 our primary outcome was incident reports of mitral regurgitation, which were identified from hospita

285 ucing good outcomes in patients with primary mitral regurgitation who are at high surgical risk.

286 l number of patients with severe symptomatic mitral regurgitation who are at too high of a risk to un

287 ion in patients with HF and severe secondary mitral regurgitation who remained symptomatic despite ma

288 h HF and moderate-severe or severe secondary mitral regurgitation who remained symptomatic despite ma

289 14) with moderate-severe or severe secondary mitral regurgitation who remained symptomatic despite ma

290 % men) with grade III+ or greater myxomatous mitral regurgitation who underwent exercise echocardiogr

291 ng 551 patients with HF and severe secondary mitral regurgitation who were alive at 1 month, those ra

292 egistry enrolling patients with degenerative mitral regurgitation with a flail leaflet in 6 tertiary

293 Among patients with degenerative mitral regurgitation with a flail leaflet referred to mi

294 r MV repair and replacement for degenerative mitral regurgitation with a flail leaflet.

295 SBP was continuously related to the risk of mitral regurgitation with no evidence of a nadir down to

296 tus and factors influencing the reduction of mitral regurgitation with or without mitral leaflet teth

297 Surgical treatment of ischemic mitral regurgitation with reduction annuloplasty is the

298 of transapical mitral valve implantation for mitral regurgitation with the TIARA device.

299 nts with moderate-severe or severe secondary mitral regurgitation with transcatheter mitral valve rep

300 sensus Decision Pathway on the Management of Mitral Regurgitation, with some sections updated and oth